Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22134613 | 0.82 | TSHR (0.37) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL30703619 | 0.81 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL667169 | 0.80 | TSHR (0.43) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL28471508 | 0.80 | TSHR (0.43) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL9645302 | 0.79 | HMGCR (0.41) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL6668200 | 0.78 | TET2 (0.50) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL6334936 | 0.78 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL6761013 | 0.78 | CYP2D6 (0.37) | TSHRGAAMEN1KMT2ACYP2D6 | |
| SCHEMBL15434694 | 0.78 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL28313432 | 0.78 | TSHR (0.37) | TSHRCYP2D6CYP2C19HIF1ATET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003988-B1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | SERVIER LAB (FR) | 2026-05-20 | — | — | EP | disclosed |
| CN-122055373-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4543868-A1 | COMPOUNDS AND METHODS FOR DEGRADING CASEIN KINASE 1 ALPHA | Pin Therapeutics, Inc. (KR) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025080879-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-17 | — | — | US | disclosed |
| CN-119451950-A | Compounds and methods for degrading casein kinase 1 alpha | 匹恩治疗株式会社 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024003749-A1 | COMPOUNDS AND METHODS FOR DEGRADING CASEIN KINASE 1 ALPHA | PIN THERAPEUTICS, INC. (KR) | 2024-01-04 | — | — | WO | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20220289734-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2022-09-15 | — | — | US | disclosed |
| EP-0311012-A2 | Glaucoma treatment | ABBOTT LABORATORIES (US) | 1989-04-12 | — | — | EP | disclosed |
| EP-0307837-A2 | Renin-inhibiting peptidyl heterocycles | ABBOTT LABORATORIES (US) | 1989-03-22 | — | — | EP | disclosed |
| EP-0295294-A1 | PEPTIDYLAMINODIOLS | ABBOTT LABORATORIES (US) | 1988-12-21 | — | — | EP | disclosed |
| US-4771071-A | ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1988-09-13 | — | — | US | disclosed |
| WO-1988005050-A1 | PEPTIDYLAMINODIOLS | ABBOTT LABORATORIES (US) | 1988-07-14 | — | — | WO | disclosed |
| EP-0258289-A1 | PEPTIDE ANALOGS | ABBOTT LABORATORIES (US) | 1988-03-09 | — | — | EP | disclosed |
| EP-0245003-A2 | Antihypercholesterolemic compounds | MERCK & CO. INC. (US) | 1987-11-11 | — | — | EP | disclosed |
| WO-1987004349-A1 | PEPTIDE ANALOGS | DELLARIA JOSEPH | 1987-07-30 | — | — | WO | disclosed |
| EP-0230266-A2 | Functionalized peptidyl aminodiols and -triols | ABBOTT LABORATORIES (US) | 1987-07-29 | — | — | EP | disclosed |
| EP-0229667-A2 | Peptidylaminodiols | ABBOTT LABORATORIES (US) | 1987-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | TSHR 140/4885HSD17B10 3693/4885MGAM 1964/4885 |
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | TSHR 4706/4885HSD17B10 812/4885MGAM 4070/4885 |
| US-20220289734-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | CASP3, BAX, CASP2 | TSHR 4066/4885HSD17B10 1273/4885MGAM 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.